RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A SYSTEMATIC REVIEW OF REAL-WORLD EVIDENCE.

Charles C WykoffHidetaka MatsumotoMark R BarakatHelene KarcherAnthony LozamaAndrew MayhookOlorunfemi A OshagbemiOlessia ZorinaTarek S HassanArshad M KhananiJeffrey S Heier

Published in: Retina (Philadelphia, Pa.) (2023)

Most RV/RO events reported after brolucizumab in early real-world practice occurred in women. Among eyes with VA measurements, approximately half experienced VA loss; overall, about one third had VA reduction of ≥0.30 logMAR at latest follow-up, with indications of regional variations.

Keyphrases

age related macular degeneration
optical coherence tomography
mycobacterium tuberculosis
healthcare
primary care
polycystic ovary syndrome
diabetic retinopathy
pregnancy outcomes
type diabetes
quality improvement
adipose tissue
metabolic syndrome